SCHEMBL6411600

SCHEMBL6411600

COCCNC(=O)C1c2ccccc2C(=O)N(C)C1c1cc(Cl)cc(Cl)c1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.65
MDM2 Q00987 1/20 0.65
ALDH1A1 P00352 5/20 0.60
MAPT P10636 3/20 0.60
HTT P42858 3/20 0.60
KDM4E B2RXH2 2/20 0.60
GLA P06280 1/20 0.58
CASP1 P29466 1/20 0.58
LMNA P02545 2/20 0.54
TSHR P16473 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
HSD17B10 Q99714 4/20 0.50
GAA P10253 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
NPC1 O15118 1/20 0.48
P2RX7 Q99572 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6413224 0.85 ALDH1A1 (0.60) TP53MDM2ALDH1A1MAPTHTT
SCHEMBL6410831 0.82 ALDH1A1 (0.58) TP53MDM2ALDH1A1MAPTHTT
SCHEMBL6410930 0.81 ALDH1A1 (0.56) TP53MDM2ALDH1A1MAPTHTT
SCHEMBL6412124 0.80 ALDH1A1 (0.56) TP53MDM2ALDH1A1MAPTHTT
SCHEMBL2099808 0.79 MDM2 (0.75) TP53MDM2ALDH1A1MAPTHTT
SCHEMBL29921815 0.79 MDM2 (0.75) TP53MDM2ALDH1A1MAPTHTT
SCHEMBL2054562 0.78 MDM2 (1.00) TP53MDM2ALDH1A1MAPTHTT
SCHEMBL14425039 0.78 ALDH1A1 (0.68) TP53MDM2ALDH1A1MAPTHTT
SCHEMBL2098874 0.78 MDM2 (1.00) TP53MDM2ALDH1A1MAPTHTT
SCHEMBL2054559 0.78 MDM2 (1.00) TP53MDM2ALDH1A1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US claimed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO claimed
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US disclosed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis CASP3, BAX, BAD TP53 24/4885MDM2 689/4885ALDH1A1 1368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.